These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 936100)

  • 1. Some aspects of the dose-response relation in urokinase administration.
    Matsuo O; Rokushima Y
    Thromb Res; 1976 May; 8(2 suppl):97-106. PubMed ID: 936100
    [No Abstract]   [Full Text] [Related]  

  • 2. Pretreatment with heparin in thrombolytic therapy with Urokinase. Heparin-urokinase therapy.
    Bizzi B; Leone G; Accorrà F
    Haemostasis; 1976; 5(3):147-54. PubMed ID: 1002001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current concepts: guidelines for the use of thrombolytic agents.
    Bell WR; Meek AG
    N Engl J Med; 1979 Dec; 301(23):1266-70. PubMed ID: 503130
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of alpha 2-plasmin inhibitor in the appearance of fibrinolytic activity during urokinase administration, and an evaluation of the optimal urokinase dosage.
    Hayashi S; Yamada K
    Thromb Res; 1979; 16(3-4):393-400. PubMed ID: 92817
    [No Abstract]   [Full Text] [Related]  

  • 5. Urokinase therapy: dose reduction by administration in plastic material.
    Zimmermann R; Schöffel G; Harenberg J
    Thromb Haemost; 1981 Jun; 45(3):296. PubMed ID: 7025343
    [No Abstract]   [Full Text] [Related]  

  • 6. Exchange of plasminogen activator between solution and intima.
    Gall W; Gurll NJ; Wright CB; Reynolds DG
    J Surg Res; 1979 May; 26(5):523-7. PubMed ID: 439883
    [No Abstract]   [Full Text] [Related]  

  • 7. High-dose, short-term local urokinase for clearing femoral thrombi by vasodilation and thrombolysis.
    Gurll NJ; Callahan W; Hufnagel HV
    J Surg Res; 1976 May; 20(5):381-8. PubMed ID: 933494
    [No Abstract]   [Full Text] [Related]  

  • 8. [Experimental studies on the mode and amount of urokinase administration in thrombolytic therapy (author's transl)].
    Matsuo O; Mihara H
    Rinsho Ketsueki; 1977 Sep; 18(9):1097-101. PubMed ID: 592505
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of thrombolytic agents.
    Wolf P
    N Engl J Med; 1980 Apr; 302(14):812. PubMed ID: 6444451
    [No Abstract]   [Full Text] [Related]  

  • 10. [Experimental aspects of the therapeutic action of urokinase in thromboembolic states].
    Danilenko MV; Stasiuk NS
    Biull Eksp Biol Med; 1981 Mar; 91(3):293-5. PubMed ID: 7018613
    [No Abstract]   [Full Text] [Related]  

  • 11. [Methods of urokinase administration based on its pharmacokinetics--pharmacokinetic approach].
    Matsuo O; Kosugi T; Mihara H
    Nihon Rinsho; 1979 Sep; 37(9):3357-61. PubMed ID: 522275
    [No Abstract]   [Full Text] [Related]  

  • 12. [Thrombolytic therapy with urokinase. Clinical trials].
    Bizzi B; Leone G; Tutinelli F; Landolfi R
    Clin Ter; 1978 Sep; 86(5):419-32. PubMed ID: 737966
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of urokinase on fibrinolysis and fibrinogenolysis.
    Matsuo O; Nishida Y; Akazawa K; Mihara H
    Jpn J Physiol; 1982; 32(5):879-83. PubMed ID: 6759739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in the reactivities of human urokinase and the porcine tissue plasminogen activator.
    Thorsen S; Astrup T
    Haemostasis; 1976; 5(5):295-305. PubMed ID: 14058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of the fibrinolytic system in experimental atheromatosis].
    Lasierra J; Díez MM; Capetillo MA; Viladés E; Gracia A; Aznar López J; Piñero J; López Campos JL; Bermudo F; Cobo R
    Sangre (Barc); 1982; 27(6):1018-29. PubMed ID: 6764034
    [No Abstract]   [Full Text] [Related]  

  • 17. [Various aspects of the platelets-urokinase interaction].
    Bastida E; Villaverde CA; Borruel MT; Valdecasas FG
    Arch Farmacol Toxicol; 1979 Dec; 5(3):270-1. PubMed ID: 397805
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of the thrombolytic effect of low urokinase concentrations.
    Matsuo O; Mihara H; Rokushima Y
    Nihon Ketsueki Gakkai Zasshi; 1976 Jun; 39(3):298-305. PubMed ID: 990007
    [No Abstract]   [Full Text] [Related]  

  • 19. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets.
    Wang X; Palasubramaniam J; Gkanatsas Y; Hohmann JD; Westein E; Kanojia R; Alt K; Huang D; Jia F; Ahrens I; Medcalf RL; Peter K; Hagemeyer CE
    Circ Res; 2014 Mar; 114(7):1083-93. PubMed ID: 24508759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolytic effect of single-chain pro-urokinase in a rabbit jugular vein thrombosis model.
    Matsuo O; Bando H; Okada K; Tanaka K; Tsukada M; Iga Y; Arimura H
    Thromb Res; 1986 Apr; 42(2):187-94. PubMed ID: 3087008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.